Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114517 · ClinicalTrials.gov registry record · Phase 2
ELITE: Early Versus Late Intervention Trial With Estradiol
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 643
- Enrollment target
NCT00114517 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 643 participants.
The verdict
NCT00114517, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 643 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the progression of early (subclinical) atherosclerosis and cognitive decline in healthy postmenopausal women.
Interventions
- OTHER Placebo
- DRUG 17B-estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 643 participants |
| Start Date | 2004-07 |
| Est. Completion | 2013-03-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00114517
The ClinicalTrials.gov registry entry for NCT00114517 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 643 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00114517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00114517 about?
NCT00114517 is a clinical study titled "ELITE: Early Versus Late Intervention Trial With Estradiol". The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the progression of early (subclinical) atherosclerosis and cognitive decline in healthy postmenopausal women.
What is the current status of trial NCT00114517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 643 participants. The study started on 2004-07. Estimated completion is 2013-03-05.
What interventions are being tested in trial NCT00114517?
The interventions under investigation include: Placebo (OTHER), 17B-estradiol (DRUG).
Who is sponsoring clinical trial NCT00114517?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.